-+ 0.00%
-+ 0.00%
-+ 0.00%

Morgan Stanley Maintains Overweight on Vertex Pharmaceuticals, Lowers Price Target to $660

Benzinga·11/03/2026 17:43:46
Listen to the news
Morgan Stanley analyst Terence Flynn maintains Vertex Pharmaceuticals (NASDAQ:VRTX) with a Overweight and lowers the price target from $665 to $660.